Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors
First-in-Human Study of DS-7300a in Subjects with Advanced Cancer
Sponsor: Daiichi Sankyo, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT5315
U.S. Govt. ID: NCT04145622
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug enters these cells and kills them without harming other cells. Some antibody-drug conjugates are used to treat cancer. Also called ADC. This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. The study will be conducted in two parts. Cancers may include bladder cancer, breast cancer, esophageal cancer, uterine cancer, head and neck/oral cancers, lung cancer, skin cancers, pancreatic cancer, prostate cancer, and bone and soft tissue cancer.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator